California’s low-cost insulin plans receive $100m manufacturing boost
Pharmaceutical Technology
JULY 15, 2022
In April, the US House of Representatives passed the Affordable Insulin Act, which set a price cap of $35 a month for Medicare and private insurance users. For almost all their insulin, these companies manufacture the API and finished dose in-house and package the products themselves instead of using CMOs, GlobalData’s Drugs database shows.
131 
Let's personalize your content